Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Tiziana Life Sciences ( (TLSA) ) is now available.
On December 15, 2025, Tiziana Life Sciences announced the withdrawal of its proposed public offering of common shares due to unfavorable market conditions. This decision reflects the company’s strategic response to the current market environment, potentially impacting its funding strategy and stakeholder interests.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. This approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.
Average Trading Volume: 323,079
Technical Sentiment Signal: Buy
Current Market Cap: $198.4M
See more data about TLSA stock on TipRanks’ Stock Analysis page.